Dr Aaron Scott BSc MSc PhD

Aaron Scott

Institute of Inflammation and Ageing
Lecturer in Respiratory Science

Contact details

Telephone
+44 (0)121 371 3257
Email
a.scott@bham.ac.uk
Twitter
@DrAAronScott
Address
University of Birmingham Research Laboratories
Centre for Translational Inflammation Research
Queen Elizabeth Hospital
Mindelsohn Way
Birmingham
B15 2WB

Dr Aaron Scott is a Lecturer in Respiratory Science, within the Institute of Inflammation and Ageing. His research focus in respiratory inflammation covers both the acute (ARDS) and chronic setting (COPD, IPF), and the development of novel therapeutics. Aaron is also very interested in the impact of alternative nicotine delivery devices - electronic cigarettes and heat-not-burn tobacco devices.

Qualifications

  • PhD, Queens University Belfast (2011)
  • MSc in Biomolecular structure and function, Queens University Belfast (2007)
  • BSc (Hons) Biochemistry, Queens University Belfast (2006)

Biography

Dr Aaron Scott studied Biochemistry at Queens University Belfast, where he also completed a Masters in Biomolecular structure and function. He then transitioned from biochemistry, to inflammatory lung disease during his PhD, in which he examined the role of immunomodulatory proteins in Cystic Fibrosis. Following completion of his doctoral studies Aaron moved to Cancer Sciences at the University of Birmingham to identify human monoclonal antibodies directed against alloantigens in the sera of sensitised individuals following solid organ transplant. In 2014 he returned to respiratory research, within the Institute of Inflammation and Ageing, examining the Mechanistic and functional importance of HSD-1 activity in ARDS.

In 2017, Dr Scott was made a lecturer in Respiratory Science. Dr. Scott has a strong interest in development of novel therapeutics for both acute and chronic inflammatory lung disease and in the investigation of the underlying disease mechanisms. In addition he has developed an interest in the impact of electronic cigarettes and heat-not-burn devices on lung health.

Teaching

Postgraduate

MSc in Immunology and Immunotherapy

Undergraduate

BSc Biomedical Science – Pharmacology

Postgraduate supervision

Aaron will supervise one PhD to begin study in September and is currently co-supervising one PhD student.

Aaron has as also previously supervised MSc/MRes research projects.

Research

In the context of both acute and chronic inflammatory lung diseases (ARDS, Pneumonia, COPD, IPF), Aaron has 2 main research themes

Investigating the underlying disease mechanisms and Development of novel immunomodulatory interventions for inflammatory lung disease.

Dr Scott is also currently investigating the effects of alternative nicotine delivery devices on lung health.

Dr Scott also retains a strong interest in areas of previous research, including investigating the importance of, and functional mechanism of, Vitamin D in inflammation.

Dr Scott also works closely with the Birmingham Acute Care Research (BACR) group, currently helping to develop several translational studies.

Other activities

Aaron is a reviewer for a number of journals and is a member of the European respiratory society (ERS), British thoracic society (BTS) and British association for lung research (BALR).

Recent Oral Presentationss Conference Abstracts

Scott A, Lugg S, Aldridge K,  D'Souza V, Dosanjh D, Dancer RCA, Thickett DR, Vaped e-cigarette condensate is more cytotoxic than unvaped ECL on alveolar macrophages. ERJ 2017: ERS Milan; Oral presentation.

Scott A, Lugg S, D'Souza V, Aldridge K, Dosanjh D, Naidu B, Thickett DR. Effects of vaped e-cigarette liquid condensate upon human alveolar macrophage function. To vape or not to vape that is the question? Thorax 2016: BTS winter meeting; Oral presentation. 

Recent Poster Presentations Conference Abstracts

Scott A, Lugg S, Aldridge K,  D'Souza V, Dosanjh D, Dancer RCA, Thickett DR, Vaped e-cigarette condensate is more cytotoxic than unvaped ECL on alveolar macrophages. ERJ 2017: ERS lung science; Poster presentation.

Scott A, Lugg S, Aldridge K,  D'Souza V, Dosanjh D, Dancer RCA, Naidu B, Thickett DR. Vaped e-cigarette condensate is more cytotoxic than unvaped ECL on alveolar macrophages. ERJ 2016: ERS London; Poster discussion

Publications

1. Patel J, Sapey E, Parekh D, Scott A, Dosanj D, Smith FG and Thickett DR. Sepsis induces a dysregulated neutrophil phenotype that is associated with increased mortality. Hindawi April 2018

2. Scott A, Glasgow A, Small D, McCrudden M, McLean D, Brown R, Doherty D, Lundy FT, Hamid UI, O’Kane CM, McAuley DF, Brodlie M, Elborn JS, Irwin CR, Timson DJ, Weldon S, Taggart CC. Characterisation of eppin function: novel sites of expression and activity in the lung. Eur Respir J 2017; 50: 1601937 Impact factor 10.569 

3. Parekh D, Patel J, Scott A, Lax S, Dancer RCA, D’Souza V, Greenwood H, Fraser WD, Gao F, Sapey E,  Perkins GD , Thickett DR. Vitamin D deficiency in human and murine sepsis. Crit Care Med. 2017; 45(2):282-289 Impact factor 7.422

4. Glasgow AMA, Small DM, Scott A, McLean DT, Camper N, Hamid U, Hegarty S, Parekh D, O’Kane C, Lundy FT, McNally P, Elborn JS, McAuley DF, Weldon S, Taggart CC. A role for whey acidic protein four-disulphide-core 12 (WFDC12) in the regulation of the inflammatory response in the lung. Thorax March 2015; 70(5):426-32 Impact factor 8.272

5. Scott A, Weldon S, Buchanan PJ, Schock B, Ernst RK, McAuley DF, Tunney MM, Irwin CR, Elborn JS, Taggart CC. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One. 2011; 6(10):e26525 Impact factor 3.234

6. Scott A, Weldon S, Taggart CC. SLPI and elafin: multifunctional antiproteases of the WFDC family. Biochem Soc Trans 2011 Oct; 39(5):1437-40 Impact factor 2.765

7. Zaric SS, Coulter WA, Shelburne CE, Fulton CR, Zaric MS, Scott A, Lappin MJ, Fitzgerald DC, Irwin CR, Taggart CC..Altered Toll-like receptor 2-mediated endotoxin tolerance is related to diminished interferon beta production. J Biol Chem. 2011; 26;286(34):29492-500. Impact factor 4.125

8. Scott A, D.J Timson. Characterization of the Saccharomyces cerevisiae galactose mutarotase/UDP-galactose 4-epimerase protein, Gal10p. FEMS Yeast Res. 2007; 7(3):366-71. Impact factor 2.479